Abstract
Atopic dermatitis is a chronic multifactorial inflammatory skin disease with a prevalence of 1-3% in adults and 15 to 20% in the world's pediatric population, that poses a significant burden on patients' quality of life. In recent years, there has been increasing evidence of multiple comorbidities associated with atopic dermatitis including not only atopic conditions such as hay fever or asthma, but also ocular complications, cardiovascular and autoimmune diseases.
Dupilumab is the first approved fully human monoclonal antibody for the treatment of moderate to severe atopic dermatitis. It blocks IL-4 receptor-signaling of both IL-4 and IL-13.
We describe a case of a 31-year-old male patient who has suffered from severe atopic dermatitis since early childhood.